| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/27/2001 | US6207683 Benzocycloheptathiophene compounds |
| 03/27/2001 | US6207678 Used for treating inflammatory disease such as arthritis, psoriasis, asthma or inflammatory bowel disease, central nervous system disorder such as anxiety, depression, dementia or psychosis, gastrointestinal disorders |
| 03/27/2001 | US6207675 For prophylaxis and therapy of diseases in which are involved viruses of the herpes family and/or cytokines in particular tumor nercosis factor-alpha |
| 03/27/2001 | US6207672 Cyclic and heterocyclic N-substituted α-iminohydroxamic and carboxyclic acids |
| 03/27/2001 | US6207669 In treatment of cancer and psoriasis |
| 03/27/2001 | US6207665 To treat inflammatory disorders in humans |
| 03/27/2001 | US6207663 Vitronectin receptor antagonists, their preparation and use |
| 03/27/2001 | US6207660 Texaphyrin conjugates and uses thereof |
| 03/27/2001 | US6207653 Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus |
| 03/27/2001 | US6207646 Immunostimulatory nucleic acid molecules |
| 03/27/2001 | US6207642 Member of the TNF family useful for treatment and diagnosis of disease |
| 03/27/2001 | US6207453 A replication-defective adeno-associated virus vector containing exogenous dna bound to a dna which codes for a rep protein; gene therapy |
| 03/27/2001 | US6207413 Nucleotide sequence coding binding protein; for the diagnosis and treatment of endocrine defects |
| 03/27/2001 | US6207412 Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cells |
| 03/27/2001 | US6207403 Kinesin motor modulators derived from the marine sponge Adocia |
| 03/27/2001 | US6207195 Sodium 4-phenylbutyrate in solid nanosphere formed by coacervation of a polycation, i.e., a protein and a polyanion, i.e., a nucleic acid; treatment of cystic fibrosis |
| 03/27/2001 | US6206917 Differential treatment of prosthetic devices |
| 03/27/2001 | CA2198217C Use of selegiline to prolong life span |
| 03/27/2001 | CA2104196C Methods of combating pneumocystis carinii pneumonia and compounds useful therefor |
| 03/27/2001 | CA2091562C Indole derivatives useful in psychotherapeutics |
| 03/27/2001 | CA2076540C Recombinant antibodies specific for tnf-.alpha. |
| 03/27/2001 | CA2065860C Inhibiting transforming growth factor .beta. to prevent accumulation of extracellular matrix |
| 03/22/2001 | WO2001020038A1 Novel cell cycle checkpoint genes and proteins encoded thereby |
| 03/22/2001 | WO2001020034A2 Methods and compositions for the screening of cell cycle modulators |
| 03/22/2001 | WO2001020031A2 Polymorphisms in a klotho gene |
| 03/22/2001 | WO2001020026A2 POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS |
| 03/22/2001 | WO2001020025A2 Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications |
| 03/22/2001 | WO2001020004A2 Protein phosphatase and kinase proteins |
| 03/22/2001 | WO2001019986A1 Peptide leukotriene receptor |
| 03/22/2001 | WO2001019983A1 Human g-protein coupled receptor |
| 03/22/2001 | WO2001019977A1 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 03/22/2001 | WO2001019973A2 Nicotinic acetylcholine receptor: alpha10 subunit |
| 03/22/2001 | WO2001019955A2 Lysosomal targeting pathway enzymes |
| 03/22/2001 | WO2001019855A2 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 03/22/2001 | WO2001019849A1 A process for the preparation of h-tyr-d-ala-phe(f)-phe-nh¿2? |
| 03/22/2001 | WO2001019847A1 A binding motif of a receptor |
| 03/22/2001 | WO2001019836A1 Phosphonic acid derivatives having carboxypeptidase b inhibitory activity |
| 03/22/2001 | WO2001019833A1 Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists |
| 03/22/2001 | WO2001019831A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 03/22/2001 | WO2001019830A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 03/22/2001 | WO2001019829A2 Pyrazolopyrimidines as therapeutic agents |
| 03/22/2001 | WO2001019826A2 Triazolopyrimidine derivatives |
| 03/22/2001 | WO2001019825A1 Pteridinones as kinase inhibitors |
| 03/22/2001 | WO2001019815A1 Novel 2-(2-pyridyl)pyrimidine derivatives |
| 03/22/2001 | WO2001019807A1 2-imino-1,3-thiazine derivatives |
| 03/22/2001 | WO2001019798A2 INHIBITORS OF FACTOR Xa |
| 03/22/2001 | WO2001019797A2 HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| 03/22/2001 | WO2001019795A1 Azacycloalkanone serine protease inhibitors |
| 03/22/2001 | WO2001019794A2 Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents |
| 03/22/2001 | WO2001019790A1 Prostaglandin derivatives |
| 03/22/2001 | WO2001019789A1 Prostaglandin derivatives |
| 03/22/2001 | WO2001019778A1 Novel dicarboxylic acid derivatives with pharmaceutical properties |
| 03/22/2001 | WO2001019770A2 Rxr modulators with improved pharmacologic profile |
| 03/22/2001 | WO2001019407A2 Taxane prodrugs |
| 03/22/2001 | WO2001019406A2 Amphiphilic prodrugs |
| 03/22/2001 | WO2001019397A1 Methods and compositions utilizing rad51 |
| 03/22/2001 | WO2001019390A1 Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
| 03/22/2001 | WO2001019379A2 Methods for treating muscular dystrophy with bone marrow cells |
| 03/22/2001 | WO2001019369A1 Use of thienopyrimidines |
| 03/22/2001 | WO2001019361A2 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 03/22/2001 | WO2001019360A2 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| 03/22/2001 | WO2001019356A2 High lipid diet |
| 03/22/2001 | WO2001019340A1 Dispersion formulations containing lipase inhibitors |
| 03/22/2001 | WO2001019339A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 03/22/2001 | WO2001019337A2 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| 03/22/2001 | WO2001019323A1 Tyrosinase activity inhibitors and cosmetics |
| 03/22/2001 | WO2001019320A2 Phospholipid prodrugs of anti-proliferative drugs |
| 03/22/2001 | WO2001001749A3 FVIIa ANTAGONISTS |
| 03/22/2001 | WO2001000811A3 17867, a novel human aminopeptidase |
| 03/22/2001 | WO2000078341A8 A method for the prophylaxis and/or treatment of medical disorders |
| 03/22/2001 | WO2000074629A3 Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal |
| 03/22/2001 | WO2000073323A3 Adam polynucleotides and polypeptides |
| 03/22/2001 | WO2000069255A8 Anti-inflammatory therapy for inflammatory mediated infection |
| 03/22/2001 | WO2000059943A3 MONOCLONAL ANTIBODIES AGAINST HUMAN PROTEIN Mcm3, PROCESS FOR THEIR PRODUCTION, AND THEIR USE |
| 03/22/2001 | WO2000059899A8 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them |
| 03/22/2001 | WO2000055155A3 Heterocyclic compounds as adenosine deaminase inhibitors |
| 03/22/2001 | WO2000040612A9 Insulin-like growth factor (igf) i mutant variants |
| 03/22/2001 | WO2000040576A3 Thiopyran compounds as inhibitors of mmp |
| 03/22/2001 | WO2000035435A9 Use of a mek inhibitor for preventing transplant rejection |
| 03/22/2001 | WO2000020591A9 Tgf-beta superfamily mutant members, including morphogenic proteins |
| 03/22/2001 | WO2000018421A9 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 03/22/2001 | WO1999067809A9 Compositions and methods for inhibiting bone resorption |
| 03/22/2001 | WO1999063936A8 Novel therapeutic agents that modulate endothelin receptors |
| 03/22/2001 | WO1999051240A8 Acylbenzoxazines for enhancing synaptic response(s) |
| 03/22/2001 | DE19944604A1 Aminderivate Amine derivatives |
| 03/22/2001 | CA2393896A1 Pteridinones as kinase inhibitors |
| 03/22/2001 | CA2387123A1 Use of thienopyrimidines |
| 03/22/2001 | CA2385747A1 Pyrazolopyrimidines as therapeutic agents |
| 03/22/2001 | CA2385589A1 Inhibitors of factor xa |
| 03/22/2001 | CA2385065A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 03/22/2001 | CA2384757A1 2-imino-1,3-thiazine derivatives |
| 03/22/2001 | CA2384733A1 Methods and compositions utilizing rad51 |
| 03/22/2001 | CA2384715A1 Prostaglandin derivatives |
| 03/22/2001 | CA2384646A1 Taxane prodrugs |
| 03/22/2001 | CA2384645A1 Amphiphilic prodrugs |
| 03/22/2001 | CA2384445A1 Methods and compositions for the screening of cell cycle modulators |
| 03/22/2001 | CA2384294A1 Nicotinic acetylcholine receptor: alpha10 subunit |
| 03/22/2001 | CA2384247A1 Azacycloalkanone serine protease inhibitors |
| 03/22/2001 | CA2384246A1 Glucosamine and egg reducing inflammation |
| 03/22/2001 | CA2383988A1 Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents |